# Abatacept for SLE Arthritis (IM101-330)

> **NCT02429934** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of California, Los Angeles** · enrollment: 28 (actual)

## Conditions studied

- Systemic Lupus Erythematosus Arthritis

## Interventions

- **BIOLOGICAL:** abatacept also known as Orencia also known as CTLA4-Ig
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02429934
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2019-09-01
- **Final completion:** 2019-09-01
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Response rate in placebo group for primary outcome was 100% on interim analysis.
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429934, "Abatacept for SLE Arthritis (IM101-330)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02429934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*